Table 3 Represents the results of the included studies
Study ID | Arms | % of THVC, Mean (SD) | %of RHVC, Mean (SD) | % of LHVC, Mean (SD) | Cognitive Assessment |
|---|---|---|---|---|---|
Dubois [20] | Placebo | -3.47 (3.069) | -3.45 (0.36) | -3.64 (0.39) | No Sig. difference between treatment groups |
Donepezil 10 mg | -1.89 (3.079) | -2.02 (0.39) | -1.81 (0.41) | ||
Hashimoto [21] | Placebo | -5.04 (2.84) | - | - | - |
Donepezil 5 mg | -3.82 (2.54) | - | - | ||
Jack [22] | Placebo | -5.44 (3.2) | - | - | Statistically significant (p < 0.001) of correlation (spearman r of -0.38 for MMSE and − 0.49 for CDR) |
Donepezil 10 mg | -4.6 (2.18) | - | - | ||
Vitamin E (2000 U/I) | -4.86 (2.5) | - | - | - | |
Krishnan [23] | Placebo | -8.2 (9.9) | -7.6 (12) | -7.8 (10.5) | - |
Donepezil 10 mg | -0.4 (2.9) | 1.4 (16) | -1.7 (15) | ||
Prins [24] | Placebo | -0.24 (2.937) | - | - | - |
Galantamine | - | - | |||
Roman [25] | Placebo | 0.54 (9.421) | - | - | - |
Donepezil 5 mg | -0.71 (9.715) | - | - | ||
Schuff [26] | Placebo | -2.23 (7.155) | -2.39 (8.273) | -2.03 (8.497) | - |
Donepezil 10 mg | -1.64 (6.763) | -1.19 (7.89) | -1.96 (8.095) | ||
Traini [27] | Donepezil 10 mg | - | There was a statistically significant difference in favor of Donepezil 10 mg plus Choline Alphoscerate (D + C). | - | |
Donepezil 10 mg + Choline Alphoscerate | - | ||||
Moon [28] | Placebo | donepezil-treated patients have reduced rate of hippocampal atrophy (p < 0.001) | - | - | K-MMSE scores in donepezil-treated patients are positively correlated with GM volume of the Hippocampus (p = 0.001) |
Donepezil 10 mg | - | - | |||
Control | - | - | |||